The application of engineered liver tissues for novel drug discovery

Expert Opinion on Drug Discovery

Volumn 10, Issue 5, 2015, Pages 519-540

  Lin, Christine ^a   Ballinger, Kimberly R ^a   Khetani, Salman R ^a  

^a Engineering Research Center and Hydraulics Laboratory   (United States)

Author keywords

Hepatitis B virus; Hepatitis C virus; Hepatocellular carcinoma; Humanized rodents; Induced pluripotent stem cells; Liver fibrosis; Malaria; Microfabrication; Microfluidics; Micropatterned co cultures; Non alcoholic fatty liver disease; Primary human hepatocytes

Indexed keywords

RECOMBINANT ENZYME;

CELL CULTURE; CELL INTERACTION; CELL LINE; CELLS BY BODY ANATOMY; COCULTURE; COMPUTER MODEL; COST BENEFIT ANALYSIS; DISEASES; DRUG EFFECT; DRUG SCREENING; FATTY LIVER; HEPATITIS B; HEPATITIS C; HUMAN; LIVER; LIVER CELL; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER FIBROSIS; LIVER MICROSOME; LIVER SLICE; MALARIA; MICROFLUIDIC ANALYSIS; MICROSOME; MICROTECHNOLOGY; NONHUMAN; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REVIEW; RODENT; STROMA CELL; TISSUE ENGINEERING; ANIMAL; CYTOLOGY; DRUG DESIGN; DRUG DEVELOPMENT; DRUG-INDUCED LIVER INJURY; LIVER DISEASES; METABOLISM; PROCEDURES; SPECIES DIFFERENCE;

ANIMALS; DRUG DESIGN; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; DRUG-INDUCED LIVER INJURY; HEPATOCYTES; HUMANS; INDUCED PLURIPOTENT STEM CELLS; LIVER; LIVER DISEASES; SPECIES SPECIFICITY; TISSUE ENGINEERING;

EID: 84928310555     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2015.1032241     Document Type: Review

References (174)

1. Rawlins MD. Cutting the cost of drug development? Nat Rev Drug Discov 2004;3:360-4
2. Kaitin KI. Deconstructing the drug development process: the new face of innovation. Clin Pharmacol Ther 2010;87:356-61
3. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3:711-15
4. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 2005;4:489-99
5. Smith BW, Adams LA. Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. Nat Rev Endocrinol 2011;7:456-65
6. Cusi K. Nonalcoholic fatty liver disease in type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 2009;16:141-9
7. Koppe SWP. Obesity and the liver: nonalcoholic fatty liver disease. Transl Res 2014;164:312-22
8. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108
9. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009;27:1485-91
10. Shih H, Pickwell GV, Guenette DK, et al. Species differences in hepatocyte induction of CYP1A1 and CYP1A2 by omeprazole. Hum Exp Toxicol 1999;18:95-105
11. Gerets HHJ, Tilmant K, Gerin B, et al. Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biol Toxicol 2012;28:69-87
12. Lauer B, Tuschl G, Kling M, Mueller SO. Species-specific toxicity of diclofenac and troglitazone in primary human and rat hepatocytes. Chem Biol Interact 2009;179:17-24
13. Khetani SR, Berger DR, Ballinger KR, et al. Microengineered liver tissues for drug testing. J Lab Autom 2015. [Epub ahead of print]
14. LeCluyse EL, Witek RP, Andersen ME, Powers MJ. Organotypic liver culture models: meeting current challenges in toxicity testing. Crit Rev Toxicol 2012;42:501-48
15. Godoy P, Hewitt NJ, Albrecht U, et al. Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol 2013;87:1315-530
16. Katoh M, Tateno C, Yoshizato K, Yokoi T. Chimeric mice with humanized liver. Toxicology 2008;246:9-17
17. Yoshizato K, Tateno C. A mouse with humanized liver as an animal model for predicting drug effects and for studying hepatic viral infection: where to next? Expert Opin Drug Metab Toxicol 2013;9:1419-35
18. Khetani SR, Bhatia SN. Engineering tissues for in vitro applications. Curr Opin Biotechnol 2006;17:524-31
19. Dash A, Inman W, Hoffmaster K, et al. Liver tissue engineering in the evaluation of drug safety. Expert Opin Drug Metab Toxicol 2009;5:1159-74
20. Khetani SR, Bhatia SN. Microscale culture of human liver cells for drug development. Nat Biotechnol 2008;26:120-6
21. Ploss A, Khetani SR, Jones CT, et al. Persistent hepatitis C virus infection in microscale primary human hepatocyte cultures. Proc Natl Acad Sci USA 2010;107:3141-5
22. Shlomai A, Schwartz RE, Ramanan V, et al. Modeling host interactions with hepatitis B virus using primary and induced pluripotent stem cell-derived hepatocellular systems. Proc Natl Acad Sci USA 2014;111;12193-8
23. Obach RS. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 1999;27:1350-9
24. Fasinu P, Bouic PJ, Rosenkranz B. Liver-based in vitro technologies for drug biotransformation studies-a review. Curr Drug Metab 2012;13:215-24
25. Caswell JM, O'Neill M, Taylor SJC, Moody TS. Engineering and application of P450 monooxygenases in pharmaceutical and metabolite synthesis. Curr Opin Chem Biol 2013;17:271-5
26. Landwehr M, Carbone M, Otey CR, et al. Diversification of catalytic function in a synthetic family of chimeric cytochrome p450s. Chem Biol 2007;14:269-78
27. Sawayama AM, Chen MMY, Kulanthaivel P, et al. A panel of cytochrome P450 BM3 variants to produce drug metabolites and diversify lead compounds. Chemistry (Easton) 2009;15:11723-9
28. Dietrich JA, Yoshikuni Y, Fisher KJ, et al. A novel semi-biosynthetic route for artemisinin production using engineered substrate-promiscuous P450(BM3). ACS Chem Biol 2009;4:261-7
29. Lee MY, Kumar RA, Sukumaran SM, et al. Three-dimensional cellular microarray for high-throughput toxicology assays. Proc Natl Acad Sci USA 2008;105:59-63
30. Lee MY, Park CB, Dordick JS, Clark DS. Metabolizing enzyme toxicology assay chip (MetaChip) for high-throughput microscale toxicity analyses. Proc Natl Acad Sci USA 2005;102:983-7
31. Guillouzo A. Liver cell models in in vitro toxicology. Environ Health Perspect 1998;106(Suppl 2):511-32
32. Lecluyse EL. Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. Eur J Pharm Sci 2001;13:343-68
33. Bhatia SN, Balis UJ, Yarmush ML, Toner M. Effect of cell-cell interactions in preservation of cellular phenotype: cocultivation of hepatocytes and nonparenchymal cells. FASEB J 1999;13:1883-900
34. Sellaro TL, Ranade A, Faulk DM, et al. Maintenance of human hepatocyte function in vitro by liver-derived extracellular matrix gels. Tissue Eng Part A 2010;16:1075-82
35. Flaim CJ, Chien S, Bhatia SN. An extracellular matrix microarray for probing cellular differentiation. Nat Methods 2005;2:119-25
36. Bhatia SN, Yarmush ML, Toner M. Controlling cell interactions by micropatterning in co-cultures: hepatocytes and 3T3 fibroblasts. J Biomed Mater Res 1997;34:189-99
37. Chen CS, Mrksich M, Huang S, et al. Geometric control of cell life and death. Science 1997;276:1425-8
38. Khademhosseini A, Langer R, Borenstein J, Vacanti JP. Microscale technologies for tissue engineering and biology. Proc Natl Acad Sci USA 2006;103:2480-7
39. Meyvantsson I, Beebe DJ. Cell culture models in microfluidic systems. Annu Rev Anal Chem (Palo Alto Calif) 2008;1:423-49
40. Ukairo O, Kanchagar C, Moore A, et al. Long-term stability of primary rat hepatocytes in micropatterned cocultures. J Biochem Mol Toxicol 2013;27:204-12
41. Wang WW, Khetani SR, Krzyzewski S, et al. Assessment of a micropatterned hepatocyte coculture system to generate major human excretory and circulating drug metabolites. Drug Metab Dispos 2010;38:1900-5
42. Khetani SR, Kanchagar C, Ukairo O, et al. Use of micropatterned cocultures to detect compounds that cause drug-induced liver injury in humans. Toxicol Sci 2013;132:107-17
43. Cho CH, Park J, Tilles AW, et al. Layered patterning of hepatocytes in co-culture systems using microfabricated stencils. Biotechniques 2010;48:47-52
44. You J, Shin D-S, Patel D, et al. Multilayered heparin hydrogel microwells for cultivation of primary hepatocytes. Adv Healthc Mater 2014;3:126-32
45. Zinchenko YS, Coger RN. Engineering micropatterned surfaces for the coculture of hepatocytes and Kupffer cells. J Biomed Mater Res A 2005;75:242-8
46. Zinchenko YS, Schrum LW, Clemens M, Coger RN. Hepatocyte and kupffer cells co-cultured on micropatterned surfaces to optimize hepatocyte function. Tissue Eng 2006;12:751-61
47. Nguyen TV, Ukairo O, Khetani SR, et al. Establishment of a hepatocyte-kupffer cell co-culture model for assessment of proinflammatory cytokine effects on metabolizing enzymes and drug transporters. Drug Metab Dispos 2015;doi:10.1124/dmd.114.061317
48. Giugliano S, Kriss M, Golden-Mason L, et al. Hepatitis C virus infection induces autocrine interferon signaling by human liver endothelial cells and release of exosomes, which inhibits viral replication. Gastroenterology 2015;148:392-402; e13
49. Kmieć Z. Cooperation of liver cells in health and disease. Adv Anat Embryol Cell Biol 2001;161:III-XIII; 1-151
50. Nahmias Y, Schwartz RE, Hu W-S, et al. Endothelium-mediated hepatocyte recruitment in the establishment of liverlike tissue in vitro. Tissue Eng 2006;12:1627-38
51. March S, Hui EE, Underhill GH, et al. Microenvironmental regulation of the sinusoidal endothelial cell phenotype in vitro. Hepatology 2009;50:920-8
52. Liu Y, Li H, Yan S, et al. Hepatocyte cocultures with endothelial cells and fibroblasts on micropatterned fibrous mats to promote liver-specific functions and capillary formation capabilities. Biomacromolecules 2014;15:1044-54
53. Olsen AL, Bloomer SA, Chan EP, et al. Hepatic stellate cells require a stiff environment for myofibroblastic differentiation. Am J Physiol Gastrointest Liver Physiol 2011;301:G110-18
54. Deleve LD, Wang X, Guo Y. Sinusoidal endothelial cells prevent rat stellate cell activation and promote reversion to quiescence. Hepatology 2008;48:920-30
55. Scott CW, Peters MF, Dragan YP. Human induced pluripotent stem cells and their use in drug discovery for toxicity testing. Toxicol Lett 2013;219:49-58
56. Schwartz RE, Fleming HE, Khetani SR, Bhatia SN. Pluripotent stem cell-derived hepatocyte-like cells. Biotechnol Adv 2014;32:504-13
57. Takebe T, Sekine K, Enomura M, et al. Vascularized and functional human liver from an iPSC-derived organ bud transplant. Nature 2013;499:481-4
58. Nagamoto Y, Tashiro K, Takayama K, et al. The promotion of hepatic maturation of human pluripotent stem cells in 3D co-culture using type I collagen and Swiss 3T3 cell sheets. Biomaterials 2012;33:4526-34
59. Javed MS, Yaqoob N, Iwamuro M, et al. Generation of hepatocyte-like cells from human induced pluripotent stem (iPS) cells by co-culturing embryoid body cells with liver non-parenchymal cell line TWNT-1. J Coll Physicians Surg Pak 2014;24:91-6
60. Berger DR, Ware BR, Davidson MD, et al. Enhancing the functional maturity of iPSC-derived human hepatocytes via controlled presentation of cell-cell interactions in vitro. Hepatology 2014;doi:10.1002/hep.27621
61. Ware BR, Berger DR, Khetani SR. Prediction of drug-induced liver injury in micropatterned co-cultures containing iPSC-derived human hepatocytes. Toxicol Sci 2015;doi:10.1093/toxsci/kfv048
62. Gieseck RL, Hannan NRF, Bort R, et al. Maturation of induced pluripotent stem cell derived hepatocytes by 3D-culture. PLoS One 2014;9:e86372
63. Shan J, Schwartz RE, Ross NT, et al. Identification of small molecules for human hepatocyte expansion and iPS differentiation. Nat Chem Biol 2013;9:514-20
64. Kostadinova R, Boess F, Applegate D, et al. A long-term three dimensional liver co-culture system for improved prediction of clinically relevant drug-induced hepatotoxicity. Toxicol Appl Pharmacol 2013;268:1-16
65. Messner S, Agarkova I, Moritz W, Kelm JM. Multi-cell type human liver microtissues for hepatotoxicity testing. Arch Toxicol 2013;87:209-13
66. Roth A, Singer T. The application of 3D cell models to support drug safety assessment: opportunities & challenges. Adv Drug Deliv Rev 2014;69-70:179-89
67. Lutolf MP, Hubbell JA. Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering. Nat Biotechnol 2005;23:47-55
68. Liu Tsang V, Liu Tsang V, Chen AA, et al. Fabrication of 3D hepatic tissues by additive photopatterning of cellular hydrogels. FASEB J 2007;21:790-801
69. Underhill GH, Chen AA, Albrecht DR, Bhatia SN. Assessment of hepatocellular function within PEG hydrogels. Biomaterials 2007;28:256-70
70. Li CY, Stevens KR, Schwartz RE, et al. Micropatterned cell-cell interactions enable functional encapsulation of primary hepatocytes in hydrogel microtissues. Tissue Eng Part A 2014;20:2200-12
71. Ozawa F, Ino K, Arai T, et al. Alginate gel microwell arrays using electrodeposition for three-dimensional cell culture. Lab Chip 2013;13:3128-35
72. Huch M, Gehart H, van Boxtel R, et al. Long-term culture of genome-stable bipotent stem cells from adult human liver. Cell 2015;160:299-312
73. Jungermann K, Kietzmann T. Zonation of parenchymal and nonparenchymal metabolism in liver. Annu Rev Nutr 1996;16:179-203
74. Kane BJ, Zinner MJ, Yarmush ML, Toner M. Liver-specific functional studies in a microfluidic array of primary mammalian hepatocytes. Anal Chem 2006;78:4291-8
75. Novik E, Maguire TJ, Chao P, et al. A microfluidic hepatic coculture platform for cell-based drug metabolism studies. Biochem Pharmacol 2010;79:1036-44
76. Sivaraman A, Leach JK, Townsend S, et al. A microscale in vitro physiological model of the liver: predictive screens for drug metabolism and enzyme induction. Curr Drug Metab 2005;6:569-91
77. Tostões RM, Leite SB, Serra M, et al. Human liver cell spheroids in extended perfusion bioreactor culture for repeated-dose drug testing. Hepatology 2012;55:1227-36
78. Lee PJ, Hung PJ, Lee LP. An artificial liver sinusoid with a microfluidic endothelial-like barrier for primary hepatocyte culture. Biotechnol Bioeng 2007;97:1340-6
79. Toh Y-C, Lim TC, Tai D, et al. A microfluidic 3D hepatocyte chip for drug toxicity testing. Lab Chip 2009;9:2026-35
80. Goral VN, Hsieh Y-C, Petzold ON, et al. Perfusion-based microfluidic device for three-dimensional dynamic primary human hepatocyte cell culture in the absence of biological or synthetic matrices or coagulants. Lab Chip 2010;10:3380-6
81. Huh D, Hamilton GA, Ingber DE. From 3D cell culture to organs-on-chips. Trends Cell Biol 2011;21:745-54
82. Viravaidya K, Sin A, Shuler ML. Development of a microscale cell culture analog to probe naphthalene toxicity. Biotechnol Prog 2004;20:316-23
83. Viravaidya K, Shuler ML. Incorporation of 3T3-L1 cells to mimic bioaccumulation in a microscale cell culture analog device for toxicity studies. Biotechnol Prog 2004;20:590-7
84. Sung JH, Shuler ML. A micro cell culture analog (microCCA) with 3-D hydrogel culture of multiple cell lines to assess metabolism-dependent cytotoxicity of anti-cancer drugs. Lab Chip 2009;9:1385-94
85. Sung JH, Kam C, Shuler ML. A microfluidic device for a pharmacokinetic-pharmacodynamic (PK-PD) model on a chip. Lab Chip 2010;10:446-55
86. Yum K, Hong SG, Healy KE, Lee LP. Physiologically relevant organs on chips. Biotechnol J 2014;9:16-27
87. Capulli AK, Tian K, Mehandru N, et al. Approaching the in vitro clinical trial: engineering organs on chips. Lab Chip 2014;14:3181-6
88. Elferink MGL, Olinga P, van Leeuwen EM, et al. Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol 2011;253:57-69
89. Vickers AEM, Bentley P, Fisher RL. Consequences of mitochondrial injury induced by pharmaceutical fatty acid oxidation inhibitors is characterized in human and rat liver slices. Toxicol In Vitro 2006;20:1173-82
90. Martignoni M, Monshouwer M, de Kanter R, et al. Phase I and phase II metabolic activities are retained in liver slices from mouse, rat, dog, monkey and human after cryopreservation. Toxicol In Vitro 2004;18:121-8
91. Edwards RJ, Price RJ, Watts PS, et al. Induction of cytochrome P450 enzymes in cultured precision-cut human liver slices. Drug Metab Dispos 2003;31:282-8
92. van Midwoud PM, Merema MT, Verweij N, et al. Hydrogel embedding of precision-cut liver slices in a microfluidic device improves drug metabolic activity. Biotechnol Bioeng 2011;108:1404-12
93. van Midwoud PM, Merema MT, Verpoorte E, Groothuis GMM. Microfluidics enables small-scale tissue-based drug metabolism studies with scarce human tissue. J Lab Autom 2011;16:468-76
94. Strom SC, Davila J, Grompe M. Chimeric mice with humanized liver: tools for the study of drug metabolism, excretion, and toxicity. Methods Mol Biol 2010;640:491-509
95. Sanoh S, Ohta S. Chimeric mice transplanted with human hepatocytes as a model for prediction of human drug metabolism and pharmacokinetics. Biopharm Drug Dispos 2014;35:71-86
96. Sanoh S, Chan T, Horiguchi A, et al. Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver. Drug Metab Dispos 2012;40:322-8
97. Foster JR, Jacobsen M, Kenna G, et al. Differential effect of troglitazone on the human bile acid transporters, MRP2 and BSEP, in the PXB hepatic chimeric mouse. Toxicol Pathol 2012;40:1106-16
98. Bateman TJ, Reddy VGB, Kakuni M, et al. Application of chimeric mice with humanized liver for study of human-specific drug metabolism. Drug Metab Dispos 2014;42:1055-65
99. Akkina R. Human immune responses and potential for vaccine assessment in humanized mice. Curr Opin Immunol 2013;25:403-9
100. Wilson EM, Bial J, Tarlow B, et al. Extensive double humanization of both liver and hematopoiesis in FRGN mice. Stem Cell Res 2014;13:404-12
101. Bility MT, Zhang L, Washburn ML, et al. Generation of a humanized mouse model with both human immune system and liver cells to model hepatitis C virus infection and liver immunopathogenesis. Nat Protoc 2012;7:1608-17
102. Chen AA, Thomas DK, Ong LL, et al. Humanized mice with ectopic artificial liver tissues. Proc Natl Acad Sci USA 2011;108:11842-7
103. Ohashi K, Marion PL, Nakai H, et al. Sustained survival of human hepatocytes in mice: a model for in vivo infection with human hepatitis B and hepatitis delta viruses. Nat Med 2000;6:327-31
104. Chen M, Zhang J, Wang Y, et al. The liver toxicity knowledge base: a systems approach to a complex end point. Clin Pharmacol Ther 2013;93:409-12
105. Judson R, Richard A, Dix D, et al. ACToR-aggregated computational toxicology resource. Toxicol Appl Pharmacol 2008;233:7-13
106. Kleinstreuer NC, Yang J, Berg EL, et al. Phenotypic screening of the ToxCast chemical library to classify toxic and therapeutic mechanisms. Nat Biotechnol 2014;32:583-91
107. Xu JJ, Henstock PV, Dunn MC, et al. Cellular imaging predictions of clinical drug-induced liver injury. Toxicol Sci 2008;105:97-105
108. Liu Z, Shi Q, Ding D, et al. Translating clinical findings into knowledge in drug safety evaluation-drug induced liver injury prediction system (DILIps). PLoS Comp Biol 2011;7:e1002310
109. Zhu X, Kruhlak NL. Construction and analysis of a human hepatotoxicity database suitable for QSAR modeling using post-market safety data. Toxicology 2014;321:62-72
110. Zurlinden TJ, Reisfeld B. Physiologically based modeling of the pharmacokinetics of acetaminophen and its major metabolites in humans using a Bayesian population approach. Eur J Drug Metab Pharmacokinet 2015;doi:10.1007/s13318-015-0253-x
111. Shoda LKM, Woodhead JL, Siler SQ, et al. Linking physiology to toxicity using DILIsym®, a mechanistic mathematical model of drug-induced liver injury. Biopharm Drug Dispos 2014;35:33-49
112. Howell BA, Yang Y, Kumar R, et al. In vitro to in vivo extrapolation and species response comparisons for drug-induced liver injury (DILI) using DILIsym™: a mechanistic, mathematical model of DILI. J Pharmacokinet Pharmacodyn 2012;39:527-41
113. Subramanian K, Raghavan S, Rajan Bhat A, et al. A systems biology based integrative framework to enhance the predictivity of in vitro methods for drug-induced liver injury. Expert Opin Drug Saf 2008;7:647-62
114. Carrolo M, Giordano S, Cabrita-Santos L, et al. Hepatocyte growth factor and its receptor are required for malaria infection. Nat Med 2003;9:1363-9
115. March S, Ng S, Velmurugan S, et al. A microscale human liver platform that supports the hepatic stages of Plasmodium falciparum and vivax. Cell Host Microbe 2013;14:104-15
116. Carlton JM, Angiuoli SV, Suh BB, et al. Genome sequence and comparative analysis of the model rodent malaria parasite Plasmodium yoelii yoelii. Nature 2002;419:512-19
117. McCutchan TF, Lal AA, la Cruz de VF, et al. Sequence of the immunodominant epitope for the surface protein on sporozoites of Plasmodium vivax. Science 1985;230:1381-3
118. Karnasuta C, Pavanand K, Chantakulkij S, et al. Complete development of the liver stage of Plasmodium falciparum in a human hepatoma cell line. Am J Trop Med Hyg 1995;53:607-11
119. Yokoo H, Kondo T, Fujii K, et al. Proteomic signature corresponding to alpha fetoprotein expression in liver cancer cells. Hepatology 2004;40:609-17
120. Mazier D, Landau I, Druilhe P, et al. Cultivation of the liver forms of Plasmodium vivax in human hepatocytes. Nature 1984;307:367-9
121. Yalaoui S, Huby T, Franetich J-F, et al. Scavenger receptor BI boosts hepatocyte permissiveness to Plasmodium infection. Cell Host Microbe 2008;4:283-92
122. Chattopadhyay R, Velmurugan S, Chakiath C, et al. Establishment of an in vitro assay for assessing the effects of drugs on the liver stages of Plasmodium vivax malaria. PLoS One 2010;5:e14275
123. Epstein JE, Tewari K, Lyke KE, et al. Live attenuated malaria vaccine designed to protect through hepatic CD8+ T cell immunity. Science 2011;334:475-80
124. Ng S, March S, Galstian A, et al. Hypoxia promotes liver stage malaria infection in primary human hepatocytes in vitro. Dis Model Mech 2013;7:215-24
125. Ng S, Schwartz RE, March S, et al. Human iPSC-derived hepatocyte-like cells support plasmodium liver-stage infection in vitro. Stem Cell Reports 2015;4:348-59
126. Morosan S, Hez-Deroubaix S, Lunel F, et al. Liver-stage development of Plasmodium falciparum, in a humanized mouse model. J Infect Dis 2006;193:996-1004
127. Vaughan AM, Mikolajczak SA, Wilson EM, et al. Complete Plasmodium falciparum liver-stage development in liver-chimeric mice. J Clin Invest 2012;122:3618-28
128. Wilkening S, Stahl F, Bader A. Comparison of primary human hepatocytes and hepatoma cell line Hepg2 with regard to their biotransformation properties. Drug Metab Dispos 2003;31:1035-42
129. Fournier C, Sureau C, Coste J, et al. In vitro infection of adult normal human hepatocytes in primary culture by hepatitis C virus. J Gen Virol 1998;79(Pt 10):2367-74
130. Carloni G, Iacovacci S, Sargiacomo M, et al. Susceptibility of human liver cell cultures to hepatitis C virus infection. Arch Virol Suppl 1993;8:31-9
131. Rumin S, Berthillon P, Tanaka E, et al. Dynamic analysis of hepatitis C virus replication and quasispecies selection in long-term cultures of adult human hepatocytes infected in vitro. J Gen Virol 1999;80(Pt 11):3007-18
132. Buck M. Direct infection and replication of naturally occurring hepatitis C virus genotypes 1; 2; 3 and 4 in normal human hepatocyte cultures. PLoS One 2008;3:e2660
133. Lázaro CA, Chang M, Tang W, et al. Hepatitis C virus replication in transfected and serum-infected cultured human fetal hepatocytes. Am J Pathol 2007;170:478-89
134. Gripon P, Diot C, Theze N, et al. Hepatitis B virus infection of adult human hepatocytes cultured in the presence of dimethyl sulfoxide. J Virol 1988;62:4136-43
135. Gripon P, Diot C, Guguen-Guillouzo C. Reproducible high level infection of cultured adult human hepatocytes by hepatitis B virus: effect of polyethylene glycol on adsorption and penetration. Virology 1993;192:534-40
136. Schwartz RE, Trehan K, Andrus L, et al. Modeling hepatitis C virus infection using human induced pluripotent stem cells. Proc Natl Acad Sci USA 2012;109:2544-8
137. Sainz B, TenCate V, Uprichard SL. Three-dimensional Huh7 cell culture system for the study of Hepatitis C virus infection. Virol J 2009;6:103
138. Tran NM, Dufresne M, Duverlie G, et al. An appropriate selection of a 3D alginate culture model for hepatic Huh-7 cell line encapsulation intended for viral studies. Tissue Eng Part A 2013;19:103-13
139. Barth H, Robinet E, Liang TJ, Baumert TF. Mouse models for the study of HCV infection and virus-host interactions. J Hepatol 2008;49:134-42
140. Dandri M, Burda MR, Torok E, et al. Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus. Hepatology 2001;33:981-8
141. Mercer DF, Schiller DE, Elliott JF, et al. Hepatitis C virus replication in mice with chimeric human livers. Nat Med 2001;7:927-33
142. Bissig K-D, Wieland SF, Tran P, et al. Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment. J Clin Invest 2010;120:924-30
143. Kamiya N, Iwao E, Hiraga N, et al. Practical evaluation of a mouse with chimeric human liver model for hepatitis C virus infection using an NS3-4A protease inhibitor. J Gen Virol 2010;91:1668-77
144. Washburn ML, Bility MT, Zhang L, et al. A humanized mouse model to study hepatitis C virus infection, immune response, and liver disease. Gastroenterology 2011;140:1334-44
145. Bility MT, Cheng L, Zhang Z, et al. Hepatitis B virus infection and immunopathogenesis in a humanized mouse model: induction of human-specific liver fibrosis and M2-like macrophages. PLoS Pathog 2014;10:e1004032
146. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-21
147. Collison KS, Saleh SM, Bakheet RH, et al. Diabetes of the liver: the link between nonalcoholic fatty liver disease and HFCS-55. Obesity (Silver Spring) 2009;17:2003-13
148. Ali R, Cusi K. New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD). Ann Med 2009;41:265-78
149. Velayudham A, Dolganiuc A, Ellis M, et al. VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. Hepatology 2009;49:989-97
150. Hebbard L, George J. Animal models of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2011;8:35-44
151. Janorkar AV, King KR, Megeed Z, Yarmush ML. Development of an in vitro cell culture model of hepatic steatosis using hepatocyte-derived reporter cells. Biotechnol Bioeng 2009;102:1466-74
152. Janorkar AV, Harris LM, Murphey BS, Sowell BL. Use of three-dimensional spheroids of hepatocyte-derived reporter cells to study the effects of intracellular fat accumulation and subsequent cytokine exposure. Biotechnol Bioeng 2011;108:1171-80
153. Gómez-Lechón MJ, Donato MT, Martínez-Romero A, et al. A human hepatocellular in vitro model to investigate steatosis. Chem Biol Interact 2007;165:106-16
154. Donato MT, Jimenez N, Serralta A, et al. Effects of steatosis on drug-metabolizing capability of primary human hepatocytes. Toxicol In Vitro 2007;21:271-6
155. Hanley AJG, Williams K, Festa A, et al. Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes 2005;54:3140-7
156. Qureshi SA, Rios Candelore M, Xie D, et al. A novel glucagon receptor antagonist inhibits glucagon-mediated biological effects. Diabetes 2004;53:3267-73
157. Davidson MD, Lehrer M, Khetani S. Hormone and drug-mediated modulation of glucose metabolism in a microscale model of the human liver. Tissue Eng Part C Methods 2014;doi:10.1089/ten.TEC.2014.0512
158. Lu Y, Zhang G, Shen C, et al. A novel 3D liver organoid system for elucidation of hepatic glucose metabolism. Biotechnol Bioeng 2012;109:595-604
159. Schuppan D, Kim YO. Evolving therapies for liver fibrosis. J Clin Invest 2013;123:1887-901
160. Van de Bovenkamp M, Groothuis GMM, Meijer DKF, Olinga P. Liver fibrosis in vitro: cell culture models and precision-cut liver slices. Toxicol In Vitro 2007;21:545-57
161. van de Bovenkamp M, Groothuis GMM, Meijer DKF, Olinga P. Precision-cut fibrotic rat liver slices as a new model to test the effects of anti-fibrotic drugs in vitro. J Hepatol 2006;45:696-703
162. Verrill C, Davies J, Millward-Sadler H, et al. Organotypic liver culture in a fluid-air interface using slices of neonatal rat and adult human tissue-a model of fibrosis in vitro. J Pharmacol Toxicol Methods 2002;48:103-10
163. Westra IM, Oosterhuis D, Groothuis GMM, Olinga P. Precision-cut liver slices as a model for the early onset of liver fibrosis to test antifibrotic drugs. Toxicol Appl Pharmacol 2014;274:328-38
164. Westra IM, Oosterhuis D, Groothuis GMM, Olinga P. The effect of antifibrotic drugs in rat precision-cut fibrotic liver slices. PLoS One 2014;9:e95462
165. Xu X-X, Liu C, Liu Y, et al. Encapsulated human hepatocellular carcinoma cells by alginate gel beads as an in vitro metastasis model. Exp Cell Res 2013;319:2135-44
166. Oshikata A, Matsushita T, Ueoka R. Enhancement of drug efflux activity via MDR1 protein by spheroid culture of human hepatic cancer cells. J Biosci Bioeng 2011;111:590-3
167. Leung M, Kievit FM, Florczyk SJ, et al. Chitosan-alginate scaffold culture system for hepatocellular carcinoma increases malignancy and drug resistance. Pharm Res 2010;27:1939-48
168. Zimmermann M, Armeanu S, Smirnow I, et al. Human precision-cut liver tumor slices as a tumor patient-individual predictive test system for oncolytic measles vaccine viruses. Int J Oncol 2009;34:1247-56
169. Benites J, Valderrama JA, Taper H, Buc-Calderon P. An in vitro comparative study with furyl-1, 4-quinones endowed with anticancer activities. Invest New Drugs 2011;29:760-7
170. Olson H, Betton G, Robinson D, et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 2000;32:56-67
171. Li AP, Lu C, Brent JA, et al. Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential. Chem Biol Interact 1999;121:17-35
172. Suter L, Schroeder S, Meyer K, et al. EU framework 6 project: predictive toxicology (PredTox)-overview and outcome. Toxicol Appl Pharmacol 2011;252:73-84
173. Mennecozzi M, Landesmann B, Harris GA, Liska R. Hepatotoxicity screening taking a mode-of-action approach using HepaRG cells and HCA. Altex Proc 2012, 1/12. Proceedings of WC8
174. Michalakis Y, Renaud F. Malaria: evolution in vector control. Nature 2009;462:298-300